BioCentury
ARTICLE | Finance

Chimerix doubles up

Chimerix grabs F round for dsDNA infections, BARDA funds for smallpox

February 21, 2011 8:00 AM UTC

Antiviral play Chimerix Inc. raked in the cash last week with a $45 million series F round and a $24.8 million contract with HHS's Biomedical Advanced Research and Development Authority (BARDA).

New investor New Leaf Venture Partners led the F round. Pappas Ventures and Morningside Group, also new investors, joined existing investors Canaan Partners; Sanderling; Alta Partners; Asset Management; and Frazier Healthcare Ventures...